PHE’s Stevens and Chou Address Variations in Cost-Effectiveness Studies of PCSK-9 Inhibitors in New Commentary for Journal of Medical Economics
PHE’s Warren Stevens and Jacquelyn Chou, along with coauthor Peter Toth, examine the markedly different cost-effectiveness study results for PCSK-9 inhibitors in a new commentary in the Journal of Medical Economics. The authors attribute the differences primarily to variations in assumptions about the risk of cardiovascular disease events. They examine what types of data are most appropriate for assessment of baseline MACE risk and are likely to yield the most accurate estimate of cost-effectiveness of PCSK-9 inhibitors for real-world patients. They argue that a systematic approach to modeling cost- effectiveness is needed.
To read the complete commentary, please click here.
In this unique one-hour webinar, Dr. Jena outlines a broader framework for assessing value to improve identification of not only the highest-value treatments, but also low-value therapies on which spending can safely be reduced.